Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

accord healthcare s.l.u. - fampridine - Πολλαπλή σκλήρυνση - Άλλα φάρμακα του νευρικού συστήματος - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod υδροχλωρική - multiple sclerosis, relapsing-remitting; colitis, ulcerative - Ανοσοκατασταλτικά - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

teva gmbh - φουμαρικό διμεθύλιο - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ανοσοκατασταλτικά - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

accord healthcare s.l.u. - φουμαρικό διμεθύλιο - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ανοσοκατασταλτικά - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ανοσοκατασταλτικά - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ανοσοκατασταλτικά - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 και 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

janssen-cilag international nv (0000003494) turnhoutseweg, 30, beerse, b-2340 - estradiol - transdermal patch - 50mcg/24h - estradiol (0000050282) 3.2mg - estradiol

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

plusultra pharma gmbh - Το sirolimus - angiofibroma; tuberous sclerosis - hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

remedica ltd (0000003171) aharnon str., lemesos, 3056 - lovastatin - tablets - 20mg - lovastatin (0075330755) 20mg - lovastatin

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - idebenone - Οπτική ατροφία, κληρονομική, leber - Άλλα ψυχοδιεγερτικά και βελτιωτικών νοημοσύνης, psychoanaleptics, - Το raxone είναι υποδειγμένο για τη θεραπεία της όρασης σε εφήβους και ενήλικες ασθενείς με leber κληρονομική οπτική νευροπάθεια (Κληρονομική).